Viewpoint Molecular Targeting closes $13M in financing

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision alpha-particle oncology therapeutics and complementary diagnostic imaging agents, announced on January 8, 2021, it has closed the third and final tranche of its Series A financing for a total of approximately $13 million.